# Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

> **NCT01003691** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Age-Related Maculopathy
- Age-Related Maculopathies
- Eye Diseases
- Retinal Degeneration
- Macular Degeneration

## Interventions

- **BIOLOGICAL:** RN6G
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01003691
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-05
- **Primary completion:** 2013-03-05
- **Final completion:** 2013-04-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01003691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01003691, "Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01003691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*